Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Primary Care

Journal Scan / Research · August 19, 2021

Safety and Immunogenicity of Heterologous vs Homologous Prime-Boost Schedules With an Adenoviral-Vectored and mRNA COVID-19 Vaccine

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Safety and Immunogenicity of Heterologous Versus Homologous Prime-Boost Schedules With an Adenoviral Vectored and mRNA COVID-19 Vaccine (Com-COV): A Single-Blind, Randomised, Non-Inferiority Trial
Lancet 2021 Aug 06;[EPub Ahead of Print], X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, JC Cameron, S Charlton, EA Clutterbuck, AM Collins, T Dinesh, A England, SN Faust, DM Ferreira, A Finn, CA Green, B Hallis, PT Heath, H Hill, T Lambe, R Lazarus, V Libri, F Long, YF Mujadidi, EL Plested, S Provstgaard-Morys, MN Ramasamy, M Ramsay, RC Read, H Robinson, N Singh, DPJ Turner, PJ Turner, LL Walker, R White, JS Nguyen-Van-Tam, MD Snape

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading